Longevity biotech sector consolidates as cellular rejuvenation giant acquires promising senescence-targeting startup.
Longevity behemoth Altos Labs has acquired senotherapeutics startup Dorian Therapeutics in a landmark deal in the emerging cellular rejuvenation space. The financial terms of the acquisition were not disclosed.
Dorian co-founder and CEO Maddalena Adorno revealed the acquisition in a post on LinkedIn, stating: “I am deeply optimistic about the current progress in aging, longevity, and cellular rejuvenation, and I am confident that this acquisition will contribute to the goal of benefiting patients worldwide.”
Stanford University spinout Dorian is focused on targeting cellular senescence, the process by which aging or damaged cells cease dividing and accumulate in tissues, contributing to age-related diseases and diminished regenerative capacity. The company has been developing small-molecule “senoblockers” designed to neutralize the harmful effects of senescent cells while reactivating the body’s natural repair mechanisms.
While the companies are taking different scientific approaches, there are clearly synergies. Altos Labs launched in 2022 with a whopping $3 billion in funding to advance cellular rejuvenation programming aimed at restoring the function of cells, tissues and organs. Dorian’s senoblockers target epigenetic regulators to reduce senescent cell burden and enhance stem cell function, effectively reawakening youthful gene expression and tissue regeneration pathways.
Dorian’s technology modulates chromatin accessibility to orchestrate cellular programs disrupted in aging and disease, with broad potential applications in age-related conditions. Its lead candidates have shown promising preclinical efficacy in models of lung fibrosis and osteoarthritis.
Despite its vast resources, Altos has yet to initiate any human clinical trials – likely a reflection of the complexities of partial epigenetic reprogramming. However, co-founder and Chief Scientist Rick Klausner hinted last year at significant preclinical breakthroughs, fueling speculation that first-in-human studies may be on the horizon.
As predicted in our recent Annual Longevity Investment Report, 2025 is shaping up to be the year when “reprogramming stops being theoretical and starts being tactical.” Together with Life Biosciences’ upcoming clinical trial, this acquisition underscores a growing momentum toward translating cellular rejuvenation science into therapeutic reality.
